Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23293039,total chromatographic run time,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,8.0,2451,DB00412,Rosiglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,3.0,2452,DB00412,Rosiglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,2.9,2453,DB00412,Rosiglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,6.1,2454,DB00412,Rosiglitazone
,23293039,retention times,"The total chromatographic run time was 8.0 min, with retention times of 3.0 and 2.9 min for MET and IS-1, respectively, and 6.1 and 4.9 min for PIO and IS-2.",Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),min,4.9,2455,DB00412,Rosiglitazone
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,96.4 to 112.8,2456,DB00412,Rosiglitazone
,23293039,recoveries,The recoveries ranged from 96.4 to 112.8% for MET and 102.1 to 104.5% for PIO.,Simultaneous determination and pharmacokinetic study of metformin and pioglitazone in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23293039/),%,102.1 to 104.5,2457,DB00412,Rosiglitazone
,19477697,total run time,Each sample was run at 0.2 ml/min for a total run time of 2.5 min per sample.,"Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),[min] / [sample],2.5,5117,DB00412,Rosiglitazone
,19477697,m/z,"Detection and quantification were performed using a mass spectrometer in selected reaction-monitoring mode with positive electrospray ionization at m/z 358.1-->135.1 for rosiglitazone, m/z 344.2-->121.1 for N-desmethyl rosiglitazone, m/z 374.1-->151.1 for p-hydroxy rosiglitazone, and m/z 361.1-->138.1 for rosiglitazone-d(3).","Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),,344.2,5118,DB00412,Rosiglitazone
,19477697,m/z,"Detection and quantification were performed using a mass spectrometer in selected reaction-monitoring mode with positive electrospray ionization at m/z 358.1-->135.1 for rosiglitazone, m/z 344.2-->121.1 for N-desmethyl rosiglitazone, m/z 374.1-->151.1 for p-hydroxy rosiglitazone, and m/z 361.1-->138.1 for rosiglitazone-d(3).","Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),,374.1,5119,DB00412,Rosiglitazone
,19477697,m/z,"Detection and quantification were performed using a mass spectrometer in selected reaction-monitoring mode with positive electrospray ionization at m/z 358.1-->135.1 for rosiglitazone, m/z 344.2-->121.1 for N-desmethyl rosiglitazone, m/z 374.1-->151.1 for p-hydroxy rosiglitazone, and m/z 361.1-->138.1 for rosiglitazone-d(3).","Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),,151.1,5120,DB00412,Rosiglitazone
,19477697,m/z,"Detection and quantification were performed using a mass spectrometer in selected reaction-monitoring mode with positive electrospray ionization at m/z 358.1-->135.1 for rosiglitazone, m/z 344.2-->121.1 for N-desmethyl rosiglitazone, m/z 374.1-->151.1 for p-hydroxy rosiglitazone, and m/z 361.1-->138.1 for rosiglitazone-d(3).","Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),,361.1,5121,DB00412,Rosiglitazone
,19477697,m/z,"Detection and quantification were performed using a mass spectrometer in selected reaction-monitoring mode with positive electrospray ionization at m/z 358.1-->135.1 for rosiglitazone, m/z 344.2-->121.1 for N-desmethyl rosiglitazone, m/z 374.1-->151.1 for p-hydroxy rosiglitazone, and m/z 361.1-->138.1 for rosiglitazone-d(3).","Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477697/),,138.1,5122,DB00412,Rosiglitazone
,22242967,time to maximal plasma concentration,"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),h,0.50,6953,DB00412,Rosiglitazone
,22242967,area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)),"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),ml⁻¹·ng,308.6,6954,DB00412,Rosiglitazone
,22242967,area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)),"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),h·ml⁻¹·ng,1594.9,6955,DB00412,Rosiglitazone
,22242967,AUC from time zero to infinity (AUC(0-∞)),"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),ml⁻¹·ng,308.6,6956,DB00412,Rosiglitazone
,22242967,AUC from time zero to infinity (AUC(0-∞)),"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),h·ml⁻¹·ng,1594.9,6957,DB00412,Rosiglitazone
,22242967,terminal elimination half-life,"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),h,4.1,6958,DB00412,Rosiglitazone
,22242967,terminal elimination half-life,"Median time to maximal plasma concentration, mean maximal plasma concentration (C(max)), area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC(0-tlqc)), AUC from time zero to infinity (AUC(0-∞)), and terminal elimination half-life for regimen A were 0.50 h, 308.6 ng ml⁻¹, 1594.9 ng h ml⁻¹, 1616.0 ng h ml⁻¹ and 4.1 h, respectively, and for regimen B they were 0.50 h, 327.6 ng ml⁻¹, 1564.5 ng h ml⁻¹, 1584.2 ng h ml⁻¹ and 4.0 h, respectively.","The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242967/),h,4.0,6959,DB00412,Rosiglitazone
,15001966,elimination half-life,"h/mL, P <.001) and the mean elimination half-life from 3.9 to 1.5 hours (P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),h,3.9 to 1.5,21692,DB00412,Rosiglitazone
,15001966,peak plasma concentration,"The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P <.01).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[ng] / [ml],537.7,21693,DB00412,Rosiglitazone
,15001966,peak plasma concentration,"The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P <.01).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[ng] / [ml],362.3,21694,DB00412,Rosiglitazone
,15001966,apparent oral clearance,"The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[l] / [h],2.8,21695,DB00412,Rosiglitazone
,15001966,apparent oral clearance,"The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[l] / [h],8.5,21696,DB00412,Rosiglitazone
,25854855,recoveries,The mean recoveries of rosiglitazone from DBS and urine were 93.30% and 92.49% respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),%,93.30,27915,DB00412,Rosiglitazone
,25854855,recoveries,The mean recoveries of rosiglitazone from DBS and urine were 93.30% and 92.49% respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),%,92.49,27916,DB00412,Rosiglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.015,27917,DB00412,Rosiglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.052,27918,DB00412,Rosiglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.023,27919,DB00412,Rosiglitazone
,25854855,limit of detections,The limit of detections and quantifications were 0.015 and 0.052 ng/mL in DBS and 0.023 and 0.075 ng/mL in urine samples respectively.,LC-MS/MS method for the determination of rosiglitazone on rat dried blood spots and rat urine: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854855/),[ng] / [ml],0.075,27920,DB00412,Rosiglitazone
,17300135,flow rate,"Troglitazone and its internal standard (IS), rosiglitazone, were separated on an ACQUITY UPLC BEH C(18) column (1.7 microm particle size, 50 x 2.1 mm i.d.) by gradient elution with water and methanol at a flow rate of 0.5 mL/min.",Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17300135/),[ml] / [min],0.5,28093,DB00412,Rosiglitazone
,17300135,cycle time,The cycle time of each analysis was 2.5 min.,Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17300135/),min,2.5,28094,DB00412,Rosiglitazone
,23064958,steady-state plasma concentration,"The mean ± SD vismodegib steady-state plasma concentration (Day 8, N = 51) was 20.6 ± 9.72 μM (range 7.93-62.4 μM).",Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064958/),μM,20.6,30393,DB00412,Rosiglitazone
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.36,41150,DB00412,Rosiglitazone
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.17,41151,DB00412,Rosiglitazone
,32045947,excretion ratio,"The excretion ratio of CAA in the 3 main pathways via bile, feces, and urine was only 5.17%.","Pharmacokinetics, Tissue Distribution, and Excretion Study of Cajanonic Acid A in Rats by UPLC-MS/MS. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045947/),%,5.17,51778,DB00412,Rosiglitazone
,30633968,IC50,Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM).,"Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,2.9,57230,DB00412,Rosiglitazone
,30633968,IC50,"The CYP2C8 IC50 of 4.5 μM in RLM for saroglitazar, supported the use of rats for this DDI study.","Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30633968/),μM,4.5,57231,DB00412,Rosiglitazone
,21055895,limit of detection,The results showed the limit of detection was 0.04 μg L(-1) and the correlation coefficient was 0.9997 for the determination of rosiglitazone in the brain.,Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),[μg] / [l],0.04,59402,DB00412,Rosiglitazone
,21055895,maximum drug concentration (C(max)),"The mean parameters, maximum drug concentration (C(max)) and the area under the concentration-time curve from time zero to time infinity (AUC(inf)), following rosiglitazone administration were 1.06±0.28 μg L(-1) and 296.82±44.67 μg min L(-1), respectively.",Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),[μg] / [l],1.06,59403,DB00412,Rosiglitazone
,21055895,area under the concentration-time curve from time zero to time infinity (AUC(inf)),"The mean parameters, maximum drug concentration (C(max)) and the area under the concentration-time curve from time zero to time infinity (AUC(inf)), following rosiglitazone administration were 1.06±0.28 μg L(-1) and 296.82±44.67 μg min L(-1), respectively.",Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),[min·μg] / [l],296.82,59404,DB00412,Rosiglitazone
,21055895,time to peak concentration (C(max) or,"The time to peak concentration (C(max) or T(max)) of rosiglitazone occurred at 105±17.10 min, and the mean elimination half-life (t(1/2)) from brain was 190.81±85.18 min after administration of rosiglitazone.",Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),min,105,59405,DB00412,Rosiglitazone
,21055895,T(max)),"The time to peak concentration (C(max) or T(max)) of rosiglitazone occurred at 105±17.10 min, and the mean elimination half-life (t(1/2)) from brain was 190.81±85.18 min after administration of rosiglitazone.",Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),min,105,59406,DB00412,Rosiglitazone
,21055895,elimination half-life (t(1/2)),"The time to peak concentration (C(max) or T(max)) of rosiglitazone occurred at 105±17.10 min, and the mean elimination half-life (t(1/2)) from brain was 190.81±85.18 min after administration of rosiglitazone.",Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21055895/),min,190.81,59407,DB00412,Rosiglitazone
,27392173,flow rate,"With an octadeuterated sildenafil as the internal standard, the drugs were separated via gradient elution using a C18 column and formic acid in methanol or in water as the mobile phase with a flow rate of 0.25mL/min.",A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27392173/),[ml] / [min],0.25,66162,DB00412,Rosiglitazone
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,130.27,66236,DB00412,Rosiglitazone
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,358.14,66237,DB00412,Rosiglitazone
,17459785,m/z,"The ion transitions monitored were m/z 130.27-->71.11 for metformin, m/z 358.14-->135.07 for rosiglitazone and m/z 206.20-->105.19 for the IS.",Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),,206.20,66238,DB00412,Rosiglitazone
,17459785,limit of detection (LOD),The limit of detection (LOD) of both metformin and rosiglitazone was 1 ng/ml.,Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17459785/),[ng] / [ml],1,66239,DB00412,Rosiglitazone
,26171322,flow rate,The flow rate was 500 μl/min along with a 5 μl injection volume.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),[μl] / [min],500,68064,DB00412,Rosiglitazone
,26171322,MR,The MRM mode of the ions for carbocisteine was 180.0 > 89.0 and for rosiglitazone it was 238.1 > 135.1.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),,180.0,68065,DB00412,Rosiglitazone
,26171322,MR,The MRM mode of the ions for carbocisteine was 180.0 > 89.0 and for rosiglitazone it was 238.1 > 135.1.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),,238.1,68066,DB00412,Rosiglitazone
,26171322,retention times,"The retention times of carbocisteine and the internal standard rosiglitazone were approximately 2.20 and 3.01 min, respectively.",Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,2.20,68067,DB00412,Rosiglitazone
,26171322,retention times,"The retention times of carbocisteine and the internal standard rosiglitazone were approximately 2.20 and 3.01 min, respectively.",Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,3.01,68068,DB00412,Rosiglitazone
,26171322,overall run time,The overall run time was 4.50 min.,Bioanalytical Method for Carbocisteine in Human Plasma by Using LC-MS/MS: A Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26171322/),min,4.50,68069,DB00412,Rosiglitazone
,20662314,percentage of,"The percentage of microspheres floating after 12 h was (91.45 +/- 1.62)%, and the DL and EE were (9.31 +/- 0.31)% and (89.55 +/- 1.65)% respectively.",Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662314/),%,91.45,69730,DB00412,Rosiglitazone
,20662314,percentage of,"The percentage of microspheres floating after 12 h was (91.45 +/- 1.62)%, and the DL and EE were (9.31 +/- 0.31)% and (89.55 +/- 1.65)% respectively.",Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662314/),%,9.31,69731,DB00412,Rosiglitazone
,20662314,percentage of,"The percentage of microspheres floating after 12 h was (91.45 +/- 1.62)%, and the DL and EE were (9.31 +/- 0.31)% and (89.55 +/- 1.65)% respectively.",Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662314/),%,89.55,69732,DB00412,Rosiglitazone
,16815107,flow rate,"Chromatographic separation was achieved with a reversed-phase Apollo C18 column and a mobile phase of methanol-acetonitrile-mixed phosphate buffer (pH 2.6; 10mM) (40:12:48, v/v/v) with a flow rate of 1.2 ml/min.",High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815107/),[ml] / [min],1.2,70588,DB00412,Rosiglitazone
,12898007,elimination half-life (t(1/2)),Gemfibrozil raised the mean area under the plasma rosiglitazone concentration-time curve (AUC) 2.3-fold (range 1.5- to 2.8-fold; p=0.00002) and prolonged the elimination half-life (t(1/2)) of rosiglitazone from 3.6 to 7.6 h ( p=0.000002).,Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,3.6,76726,DB00412,Rosiglitazone
,12898007,elimination half-life (t(1/2)),Gemfibrozil raised the mean area under the plasma rosiglitazone concentration-time curve (AUC) 2.3-fold (range 1.5- to 2.8-fold; p=0.00002) and prolonged the elimination half-life (t(1/2)) of rosiglitazone from 3.6 to 7.6 h ( p=0.000002).,Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,7.6,76727,DB00412,Rosiglitazone
,12898007,t(max),"In addition, gemfibrozil prolonged the t(max) of N-desmethylrosiglitazone from 7 to 12 h and reduced the N-desmethylrosiglitazone/rosiglitazone AUC(0-48) ratio by 38% ( p<0.01).",Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,7,76728,DB00412,Rosiglitazone
,12898007,t(max),"In addition, gemfibrozil prolonged the t(max) of N-desmethylrosiglitazone from 7 to 12 h and reduced the N-desmethylrosiglitazone/rosiglitazone AUC(0-48) ratio by 38% ( p<0.01).",Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,12,76729,DB00412,Rosiglitazone
,15606443,apparent K(i),"Inhibition of rosiglitazone para-hydroxylation by trimethoprim in vitro was found to be competitive with apparent K(i) and IC(50) values of 29 microm and 54.5 microm, respectively.",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),μm,29,85890,DB00412,Rosiglitazone
,15606443,IC(50),"Inhibition of rosiglitazone para-hydroxylation by trimethoprim in vitro was found to be competitive with apparent K(i) and IC(50) values of 29 microm and 54.5 microm, respectively.",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),μm,54.5,85891,DB00412,Rosiglitazone
,15606443,plasma AUC,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),[h·μg] / [l],2774,85892,DB00412,Rosiglitazone
,15606443,plasma AUC,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),[h·μg] / [l],3643,85893,DB00412,Rosiglitazone
,15606443,half-life,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),h,3.3,85894,DB00412,Rosiglitazone
,15606443,half-life,"In the presence of trimethoprim, rosiglitazone plasma AUC was increased by 31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549), and half-life was increased by 27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5).",The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606443/),h,4.2,85895,DB00412,Rosiglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],2024,100947,DB00412,Rosiglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],1763,100948,DB00412,Rosiglitazone
,17635496,area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)),"The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],1729,100949,DB00412,Rosiglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],6244,100950,DB00412,Rosiglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],5123,100951,DB00412,Rosiglitazone
,17635496,AUC(0-infinity),"The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14).",No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635496/),[h·ng] / [ml],4851,100952,DB00412,Rosiglitazone
,17220051,AUC0-->t,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),[h·μg] / [ml],4.80,110756,DB00412,Rosiglitazone
,17220051,AUC0-->infinity,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),[h·μg] / [ml],4.76,110757,DB00412,Rosiglitazone
,17220051,AUC0-->infinity,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),h,1.0,110758,DB00412,Rosiglitazone
,17220051,Cmax,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),[h·μg] / [ml],4.76,110759,DB00412,Rosiglitazone
,17220051,Tmax,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),[h·μg] / [ml],4.76,110760,DB00412,Rosiglitazone
,17220051,t1/2,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),h,0.8,110761,DB00412,Rosiglitazone
,17220051,t1/2,"The mean+/-SD of AUC0-->t, AUC0-->infinity, Cmax, Tmax, and t1/2 were 4.80+/-1.89 and 4.76 +/-1.94 microg x h/ml, 5.17+/-2.11 and 5.08 +/- 2.27 microg x h/ml, 0.93+/-0.24 and 0.99+/-0.34 microg/ml, 1.0 +/-0.4 and 0.8+/-0.5 h, and 5.0+/-2.0 and 5.0+/-2.0 h for the test and reference formulation, respectively.",Bioequivalence evaluation of two rosiglitazone tablet formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220051/),h,5.0,110762,DB00412,Rosiglitazone
,18677971,flow rate,The mobile phase consisting of acetonitrile:potassium di-hydrogen phosphate buffer (35:65 v/v) was used at the flow rate of 1.2 ml/min on a reverse phase C18 column.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),[ml] / [min],1.2,114108,DB00412,Rosiglitazone
above,18677971,absolute recovery,The absolute recovery was above 90% of all analytes over the concentration range of 25-2500 ng/ml for RSG and CLZ and 20-2000 ng/ ml for DCLZ.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),%,90,114109,DB00412,Rosiglitazone
,18677971,absolute recovery,The absolute recovery was above 90% of all analytes over the concentration range of 25-2500 ng/ml for RSG and CLZ and 20-2000 ng/ ml for DCLZ.,"Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18677971/),[ng] / [ml],20-2000,114110,DB00412,Rosiglitazone
,15063342,flow rate,"The isocratic mobile phase consisted of 10 mM sodium acetate-acetonitrile (pH 5; 60:40, v/v) and was delivered at a flow rate of 1 ml/min to an Alltima phenyl column (250 mm x 4.6 mm, 5 microm).",Simplified method for determination of rosiglitazone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063342/),[ml] / [min],1,122058,DB00412,Rosiglitazone
,11417440,terminal elimination half-life t1/2,"The area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was on average 12% lower (95% CI-21%, -2%) during rosiglitazone + acarbose coadministration and was accompanied by an approximate 1-h (23%) reduction in terminal elimination half-life t1/2 (4.9 h versus 3.8 h).",The effect of acarbose on the pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417440/),h,4.9,125621,DB00412,Rosiglitazone
,11417440,terminal elimination half-life t1/2,"The area under the concentration-time curve from time zero to infinity [AUC(0-infinity)] was on average 12% lower (95% CI-21%, -2%) during rosiglitazone + acarbose coadministration and was accompanied by an approximate 1-h (23%) reduction in terminal elimination half-life t1/2 (4.9 h versus 3.8 h).",The effect of acarbose on the pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417440/),h,3.8,125622,DB00412,Rosiglitazone
,16046313,steady-state plasma glucose,"After rosiglitazone treatment, insulin sensitivity improved with significant fall in steady-state plasma glucose (means +/- SE from 13.5 +/- 0.62 to 9.8 +/- 1.02 mmol/l, P < 0.001).","Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046313/),[mM] / [l],13.5,125699,DB00412,Rosiglitazone
,16046313,steady-state plasma glucose,"After rosiglitazone treatment, insulin sensitivity improved with significant fall in steady-state plasma glucose (means +/- SE from 13.5 +/- 0.62 to 9.8 +/- 1.02 mmol/l, P < 0.001).","Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046313/),[mM] / [l],9.8,125700,DB00412,Rosiglitazone
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[h·ng] / [ml],18.5,127836,DB00412,Rosiglitazone
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[h·ng] / [ml],19.1,127837,DB00412,Rosiglitazone
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.594,127838,DB00412,Rosiglitazone
,11185675,C24,"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.579,127839,DB00412,Rosiglitazone
,11185675,C24,"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.594,127840,DB00412,Rosiglitazone
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],1,132975,DB00412,Rosiglitazone
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],15,132976,DB00412,Rosiglitazone
,20572378,Cmax,"1.02 +/- 1.50 hr of Tmax, 796.51 +/- 155.19 vs. 723.48 +/- 134.69 ng/ml of Cmax, 3.94 +/- 0.80 vs.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),[ng] / [ml],723.48,137521,DB00412,Rosiglitazone
,20572378,T1/2,"3.87 +/- 0.77 hr of T1/2, 4,308.43 +/- 1,006.28 vs. 4,135.66 +/- 1,061.96 ng x hr/ml of AUC(0-t), 4,384.65 +/- 1,035.15 vs. 4,183.87 +/- 1,075.39 ng x hr/ml of AUC(0-inf), respectively.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),h,3.87,137522,DB00412,Rosiglitazone
,20572378,AUC(0-t),"3.87 +/- 0.77 hr of T1/2, 4,308.43 +/- 1,006.28 vs. 4,135.66 +/- 1,061.96 ng x hr/ml of AUC(0-t), 4,384.65 +/- 1,035.15 vs. 4,183.87 +/- 1,075.39 ng x hr/ml of AUC(0-inf), respectively.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),[h·ng] / [ml],"4,308.43",137523,DB00412,Rosiglitazone
,20572378,AUC(0-t),"3.87 +/- 0.77 hr of T1/2, 4,308.43 +/- 1,006.28 vs. 4,135.66 +/- 1,061.96 ng x hr/ml of AUC(0-t), 4,384.65 +/- 1,035.15 vs. 4,183.87 +/- 1,075.39 ng x hr/ml of AUC(0-inf), respectively.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),[h·ng] / [ml],"4,135.66",137524,DB00412,Rosiglitazone
,20572378,AUC(0-inf),"3.87 +/- 0.77 hr of T1/2, 4,308.43 +/- 1,006.28 vs. 4,135.66 +/- 1,061.96 ng x hr/ml of AUC(0-t), 4,384.65 +/- 1,035.15 vs. 4,183.87 +/- 1,075.39 ng x hr/ml of AUC(0-inf), respectively.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),[h·ng] / [ml],"4,384.65",137525,DB00412,Rosiglitazone
,20572378,AUC(0-inf),"3.87 +/- 0.77 hr of T1/2, 4,308.43 +/- 1,006.28 vs. 4,135.66 +/- 1,061.96 ng x hr/ml of AUC(0-t), 4,384.65 +/- 1,035.15 vs. 4,183.87 +/- 1,075.39 ng x hr/ml of AUC(0-inf), respectively.",Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20572378/),[h·ng] / [ml],"4,183.87",137526,DB00412,Rosiglitazone
,17178266,total clearance,"Mean total clearance values were 0.033 L x h(-1) x kg(-1) (95% confidence interval [CI], 0.030-0.037 L x h(-1) x kg(-1)), 0.038 L x h(-1) x kg(-1) (95% CI, 0.033-0.044 L x h(-1) x kg(-1)), and 0.046 L x h(-1) x kg(-1) (95% CI, 0.033-0.058 L x h(-1) x kg(-1)) in carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, on day 1 (P = .02, ANOVA [F test]).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h·kg],0.033,153594,DB00412,Rosiglitazone
,17178266,total clearance,"Mean total clearance values were 0.033 L x h(-1) x kg(-1) (95% confidence interval [CI], 0.030-0.037 L x h(-1) x kg(-1)), 0.038 L x h(-1) x kg(-1) (95% CI, 0.033-0.044 L x h(-1) x kg(-1)), and 0.046 L x h(-1) x kg(-1) (95% CI, 0.033-0.058 L x h(-1) x kg(-1)) in carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, on day 1 (P = .02, ANOVA [F test]).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h·kg],0.038,153595,DB00412,Rosiglitazone
,17178266,total clearance,"Mean total clearance values were 0.033 L x h(-1) x kg(-1) (95% confidence interval [CI], 0.030-0.037 L x h(-1) x kg(-1)), 0.038 L x h(-1) x kg(-1) (95% CI, 0.033-0.044 L x h(-1) x kg(-1)), and 0.046 L x h(-1) x kg(-1) (95% CI, 0.033-0.058 L x h(-1) x kg(-1)) in carriers of CYP2C8 genotypes *1/*1, *1/*3, and *3/*3, respectively, on day 1 (P = .02, ANOVA [F test]).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h·kg],0.046,153596,DB00412,Rosiglitazone
,17178266,Elimination half-lives,"Elimination half-lives were 4.3, 3.5, and 2.9 hours in CYP2C8*1/*1, *1/*3, and *3/*3 carriers, respectively.",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),h,4.3,153597,DB00412,Rosiglitazone
,17178266,Elimination half-lives,"Elimination half-lives were 4.3, 3.5, and 2.9 hours in CYP2C8*1/*1, *1/*3, and *3/*3 carriers, respectively.",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),h,3.5,153598,DB00412,Rosiglitazone
,17178266,Elimination half-lives,"Elimination half-lives were 4.3, 3.5, and 2.9 hours in CYP2C8*1/*1, *1/*3, and *3/*3 carriers, respectively.",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),h,2.9,153599,DB00412,Rosiglitazone
,17178266,Clearance,"Clearance of desmethylrosiglitazone was also higher in CYP2C8*3 allele carriers, with mean values of 1.96 L/h (95% CI, 1.42-2.69 L/h), 2.22 L/h (95% CI, 1.61-3.04 L/h), and 2.47 L/h (95% CI, 1.80-3.39 L/h), respectively (P = .03).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h],1.96,153600,DB00412,Rosiglitazone
,17178266,Clearance,"Clearance of desmethylrosiglitazone was also higher in CYP2C8*3 allele carriers, with mean values of 1.96 L/h (95% CI, 1.42-2.69 L/h), 2.22 L/h (95% CI, 1.61-3.04 L/h), and 2.47 L/h (95% CI, 1.80-3.39 L/h), respectively (P = .03).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h],2.22,153601,DB00412,Rosiglitazone
,17178266,Clearance,"Clearance of desmethylrosiglitazone was also higher in CYP2C8*3 allele carriers, with mean values of 1.96 L/h (95% CI, 1.42-2.69 L/h), 2.22 L/h (95% CI, 1.61-3.04 L/h), and 2.47 L/h (95% CI, 1.80-3.39 L/h), respectively (P = .03).",Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178266/),[l] / [h],2.47,153602,DB00412,Rosiglitazone
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[h·ng] / [ml],3825.02,153833,DB00412,Rosiglitazone
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],664.47,153834,DB00412,Rosiglitazone
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[h·ng] / [ml],4848.19,153835,DB00412,Rosiglitazone
,12043956,Cmax,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],664.47,153836,DB00412,Rosiglitazone
,12043956,Cmax,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],624.88,153837,DB00412,Rosiglitazone
,12043956,t(max),"The t(max) for rosiglitazone alone and for rosiglitazone after sucralfate treatments was 1.11 and 1.67 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,1.11,153838,DB00412,Rosiglitazone
,12043956,t(max),"The t(max) for rosiglitazone alone and for rosiglitazone after sucralfate treatments was 1.11 and 1.67 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,1.67,153839,DB00412,Rosiglitazone
,12043956,elimination half-life,"The mean elimination half-life for rosiglitazone and rosiglitazone after sucralfate treatment was 4.35 and 4.51 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,4.35,153840,DB00412,Rosiglitazone
,12043956,elimination half-life,"The mean elimination half-life for rosiglitazone and rosiglitazone after sucralfate treatment was 4.35 and 4.51 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,4.51,153841,DB00412,Rosiglitazone
,16971347,oral bioavailability,"The oral bioavailability of RGL was reduced by 19.9, 35.6, 53.8 and 72.0% in rats following pre-treatment with CSA at 0.057, 0.115, 0.230 and 0.340 g kg-1, respectively.","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,19.9,168256,DB00412,Rosiglitazone
,16971347,oral bioavailability,"The oral bioavailability of RGL was reduced by 19.9, 35.6, 53.8 and 72.0% in rats following pre-treatment with CSA at 0.057, 0.115, 0.230 and 0.340 g kg-1, respectively.","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,35.6,168257,DB00412,Rosiglitazone
,16971347,oral bioavailability,"The oral bioavailability of RGL was reduced by 19.9, 35.6, 53.8 and 72.0% in rats following pre-treatment with CSA at 0.057, 0.115, 0.230 and 0.340 g kg-1, respectively.","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,53.8,168258,DB00412,Rosiglitazone
,16971347,oral bioavailability,"The oral bioavailability of RGL was reduced by 19.9, 35.6, 53.8 and 72.0% in rats following pre-treatment with CSA at 0.057, 0.115, 0.230 and 0.340 g kg-1, respectively.","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,72.0,168259,DB00412,Rosiglitazone
,16971347,percentage binding,"The percentage binding of CSA was in the range 50-72% (at pH 2), 74-89% (at pH 4) and 97-100% (at pH 7).","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,50-72,168260,DB00412,Rosiglitazone
,16971347,percentage binding,"The percentage binding of CSA was in the range 50-72% (at pH 2), 74-89% (at pH 4) and 97-100% (at pH 7).","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,74-89,168261,DB00412,Rosiglitazone
,16971347,percentage binding,"The percentage binding of CSA was in the range 50-72% (at pH 2), 74-89% (at pH 4) and 97-100% (at pH 7).","Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971347/),%,97-100,168262,DB00412,Rosiglitazone
,15386508,flow rate,"The mobile phase was composed of acetonitrile (52%) and 20 mm ammonium acetate (48%, pH 7.5), and analysis was run at a flow rate of 0.2 mL/min with the detector operating at 247 nm for excitation wavelength and at 367 nm for emission wavelength, respectively.",Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386508/),[ml] / [min],0.2,172261,DB00412,Rosiglitazone
,15386508,recovery,"The method has a mean recovery of 97%, while the intra-day and inter-day precisions were all less than 7%.",Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386508/),%,97,172262,DB00412,Rosiglitazone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1126,176226,DB00412,Rosiglitazone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1208,176227,DB00412,Rosiglitazone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],178,176228,DB00412,Rosiglitazone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],171,176229,DB00412,Rosiglitazone
,10859151,absolute bioavailability,"The absorption of rosiglitazone was rapid and essentially complete, with absolute bioavailability estimated to be approximately 99% after oral tablet dosing and approximately 95% after oral solution dosing, and clearance was primarily metabolic.","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),%,99,185723,DB00412,Rosiglitazone
,10859151,absolute bioavailability,"The absorption of rosiglitazone was rapid and essentially complete, with absolute bioavailability estimated to be approximately 99% after oral tablet dosing and approximately 95% after oral solution dosing, and clearance was primarily metabolic.","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),%,95,185724,DB00412,Rosiglitazone
,10859151,time to maximal concentration of radio,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),h,4-6,185725,DB00412,Rosiglitazone
,10859151,time to maximal concentration of radio,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),d,5,185726,DB00412,Rosiglitazone
,10859151,elimination half-life,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),d,5,185727,DB00412,Rosiglitazone
,10859151,elimination half-life,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),h,3-7,185728,DB00412,Rosiglitazone
,26940171,absolute bioavailability,It is well absorbed with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5h.,Pioglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26940171/),%,83,193093,DB00412,Rosiglitazone
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,3.55,208115,DB00412,Rosiglitazone
,15373932,elimination half-life,"Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47%[P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4).",Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373932/),h,5.50,208116,DB00412,Rosiglitazone
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.18,208555,DB00412,Rosiglitazone
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,3.96,208556,DB00412,Rosiglitazone
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,3.83,208557,DB00412,Rosiglitazone
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.70,208558,DB00412,Rosiglitazone
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.37,208559,DB00412,Rosiglitazone
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],384.1,208560,DB00412,Rosiglitazone
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],260.2,208561,DB00412,Rosiglitazone
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],401.9,208562,DB00412,Rosiglitazone
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],345.3,208563,DB00412,Rosiglitazone
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],406.2,208564,DB00412,Rosiglitazone
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],2078,208565,DB00412,Rosiglitazone
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1249,208566,DB00412,Rosiglitazone
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1901,208567,DB00412,Rosiglitazone
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1938,208568,DB00412,Rosiglitazone
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],2158,208569,DB00412,Rosiglitazone
,19138247,T(max),In our CAPD patients the mean (+/-SD) T(max) and T(1/2) of rosiglitazone were 1.20 +/- 0.26 and 21.38 +/- 21.96 h respectively.,Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19138247/),h,1.20,208678,DB00412,Rosiglitazone
,19138247,T(1/2),In our CAPD patients the mean (+/-SD) T(max) and T(1/2) of rosiglitazone were 1.20 +/- 0.26 and 21.38 +/- 21.96 h respectively.,Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19138247/),h,21.38,208679,DB00412,Rosiglitazone
,19138247,area under the concentration-time curve (AUC((0-infinity))),The mean area under the concentration-time curve (AUC((0-infinity))) and an average maximum observed plasma concentration (C(max)) of rosiglitazone in our CAPD patients were 4203.56 +/- 2916.97 ng h/mL and 409.67 +/- 148.89 ng/mL respectively.,Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19138247/),[h·ng] / [ml],4203.56,208680,DB00412,Rosiglitazone
,19138247,maximum observed plasma concentration (C(max)),The mean area under the concentration-time curve (AUC((0-infinity))) and an average maximum observed plasma concentration (C(max)) of rosiglitazone in our CAPD patients were 4203.56 +/- 2916.97 ng h/mL and 409.67 +/- 148.89 ng/mL respectively.,Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19138247/),[ng] / [ml],409.67,208681,DB00412,Rosiglitazone
,12235921,dial,"Haemodialysis did not influence rosiglitazone pharmacokinetics, and dialytic clearance was low (0.10 1/h).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[1] / [h],0.10,213970,DB00412,Rosiglitazone
,12235921,clearance,"Haemodialysis did not influence rosiglitazone pharmacokinetics, and dialytic clearance was low (0.10 1/h).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[1] / [h],0.10,213971,DB00412,Rosiglitazone
,12235921,area under the concentration-time curve (AUC(0-infinity)),"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[h·ng] / [ml],2192,213972,DB00412,Rosiglitazone
,12235921,maximum observed plasma concentration (Cmax),"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[h·ng] / [ml],2388,213973,DB00412,Rosiglitazone
,12235921,maximum observed plasma concentration (Cmax),"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[ng] / [ml],338,213974,DB00412,Rosiglitazone
,12235921,maximum observed plasma concentration (Cmax),"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),[ng] / [ml],373,213975,DB00412,Rosiglitazone
,12235921,half-life,"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),h,3.70,213976,DB00412,Rosiglitazone
,12235921,half-life,"The mean area under the concentration-time curve (AUC(0-infinity)), the maximum observed plasma concentration (Cmax) and the half-life for rosiglitazone were similar in haemodialysis patients (non-dialysis day) and healthy individuals (2192 +/- 598 ng.h/ml versus 2388 +/- 494 ng.h/ml, 338 +/- 114 ng/ml versus 373 +/- 95 ng/ml, and 3.70 +/- 0.75 h versus 3.81 +/- 0.86 h, respectively).",Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235921/),h,3.81,213977,DB00412,Rosiglitazone
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,58.94,217569,DB00412,Rosiglitazone
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,28.03,217570,DB00412,Rosiglitazone
,12189780,flow rate,"A mobile phase consisting of phosphate buffer, acetonitrile and methanol was used at a flow rate of 1.0 ml/min on a C18 column.",HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189780/),[ml] / [min],1.0,218516,DB00412,Rosiglitazone
>,12189780,absolute recovery,The absolute recovery was > 90% and the lower limit of quantitation was 5 ng/ml.,HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189780/),%,90,218517,DB00412,Rosiglitazone
,12182252,absolute bioavailability,The absolute bioavailability of rosiglitazone was 99%.,The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224207,DB00412,Rosiglitazone
,12182252,absolute bioavailability,"In this study of 12 healthy adult male volunteers, the absolute bioavailability of rosiglitazone was 99%, and the oral and IV single-dose pharmacokinetics of rosiglitazone were unaltered by concurrent treatment with ranitidine.",The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224208,DB00412,Rosiglitazone
,21281203,maximum plasma concentration,"Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours.",Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281203/),[ng] / [ml],205.2,225840,DB00412,Rosiglitazone
,21281203,elimination half-life,"Mean ± SD maximum plasma concentration was 205.2 ± 79.1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1.4 ± 0.4 hours.",Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281203/),h,1.4,225841,DB00412,Rosiglitazone
,21281203,area under the plasma rosiglitazone concentration-versus-time curve,"The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652.2 ± 351.3 ng/h/mL).",Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281203/),[ng] / [h·ml],652.2,225842,DB00412,Rosiglitazone
,19577404,m/z transitions,"The analyte and rosiglitazone, an internal standard, were analyzed by multiple reactions monitoring (MRM) at m/z transitions of 482.0-->258.0 for CKD-501 and 358.0-->135.0 for the internal standard.","Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577404/),,482.0,241116,DB00412,Rosiglitazone
,19577404,m/z transitions,"The analyte and rosiglitazone, an internal standard, were analyzed by multiple reactions monitoring (MRM) at m/z transitions of 482.0-->258.0 for CKD-501 and 358.0-->135.0 for the internal standard.","Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577404/),,258.0,241117,DB00412,Rosiglitazone
,19577404,m/z transitions,"The analyte and rosiglitazone, an internal standard, were analyzed by multiple reactions monitoring (MRM) at m/z transitions of 482.0-->258.0 for CKD-501 and 358.0-->135.0 for the internal standard.","Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577404/),,358.0,241118,DB00412,Rosiglitazone
,19577404,m/z transitions,"The analyte and rosiglitazone, an internal standard, were analyzed by multiple reactions monitoring (MRM) at m/z transitions of 482.0-->258.0 for CKD-501 and 358.0-->135.0 for the internal standard.","Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19577404/),,135.0,241119,DB00412,Rosiglitazone
,15608135,K(i),"The mechanism of inhibition was competitive, with K(i) values ranging from 0.0092 to 0.15 microM.",Selective inhibition of human cytochrome P4502C8 by montelukast. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15608135/),μM,0.0092 to 0.15,241374,DB00412,Rosiglitazone
,22378938,k(pl),Animal handling and placebo treatment affected glucose turnover with k(pl) = 0.388 kg/mg/day.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),[kg] / [d·mg],0.388,243579,DB00412,Rosiglitazone
,22378938,I(max),The effect of rosiglitazone was described as inhibition of k(inG) with I(max) = 0.296 and IC(50) = 1.97 μg/ml.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),,0.296,243580,DB00412,Rosiglitazone
,22378938,IC(50),The effect of rosiglitazone was described as inhibition of k(inG) with I(max) = 0.296 and IC(50) = 1.97 μg/ml.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),[μg] / [ml],1.97,243581,DB00412,Rosiglitazone
,22378938,ID(50),"Weight gain was characterized with body weight input (k(s)(w)) and output (k(d)(w)), and rosiglitazone inhibited k(d)(w) with ID(50) = 96.8 mg/kg.",Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),mg,96,243582,DB00412,Rosiglitazone
,19245299,IC(50),IC(50) values ranged from 1.5 +/- 0.1 microM for CYP2C8 to 82 +/- 4 microM for CYP2D6.,In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19245299/),μM,1.5,243700,DB00412,Rosiglitazone
,19245299,IC(50),IC(50) values ranged from 1.5 +/- 0.1 microM for CYP2C8 to 82 +/- 4 microM for CYP2D6.,In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19245299/),μM,82,243701,DB00412,Rosiglitazone
,16797489,EC50,KR-62980 acted as a selective PPARgamma agonist in transactivation assay with an EC50 of 15 nM.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),nM,15,245232,DB00412,Rosiglitazone
,16797489,oral bioavailability,In vivo pharmacokinetic profile of KR-62980 revealed that the compound exhibited good oral bioavailability of 65% with a terminal elimination half-life of 2.5 h in the rat.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),%,65,245233,DB00412,Rosiglitazone
,16797489,terminal elimination half-life,In vivo pharmacokinetic profile of KR-62980 revealed that the compound exhibited good oral bioavailability of 65% with a terminal elimination half-life of 2.5 h in the rat.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),h,2.5,245234,DB00412,Rosiglitazone
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.35,250327,DB00412,Rosiglitazone
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.66,250328,DB00412,Rosiglitazone
,23307233,AUC ratios,"Predicted median AUC ratios of rosiglitazone in the presence and absence of trimethoprim ranged from 1.35 to 1.66 for ten virtual trials of subjects with the CYP2C8 1/1 genotype, which included the observed value of 1.42.",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.42,250329,DB00412,Rosiglitazone
higher,23307233,AUC ratios,"In subjects with the CYP2C8 1/3 genotype, the predicted AUC ratios for all trials were higher than the observed value of 1.18 Kirchheiner et al. (Clin Pharmacol Ther 80:657-667, 2006).",Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307233/),,1.18,250330,DB00412,Rosiglitazone
,21502071,flow rate,"A Chromolith RP-18(e) column provided chromatographic separation of the analyte using a mobile phase containing 5mM ammonium acetate in water (pH 3) and methanol (20:80) at a flow rate of 1 mL/min with an elution time as low as 2.5 min, which was followed by detection with mass spectrometry.",Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),[ml] / [min],1,251654,DB00412,Rosiglitazone
low,21502071,elution time,"A Chromolith RP-18(e) column provided chromatographic separation of the analyte using a mobile phase containing 5mM ammonium acetate in water (pH 3) and methanol (20:80) at a flow rate of 1 mL/min with an elution time as low as 2.5 min, which was followed by detection with mass spectrometry.",Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),min,2.5,251655,DB00412,Rosiglitazone
,21502071,m/,The mass transition ion-pair was followed as m/z 358.0 for rosiglitazone and m/z 308.8 for alprazolam.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),,358.0,251656,DB00412,Rosiglitazone
,21502071,m/z,The mass transition ion-pair was followed as m/z 358.0 for rosiglitazone and m/z 308.8 for alprazolam.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),,308.8,251657,DB00412,Rosiglitazone
,21502071,overall recovery,The overall recovery of rosiglitazone was 95.9%.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),%,95.9,251658,DB00412,Rosiglitazone
,21502071,flow rate,A Chromolith RP-18(e) column provided chromatographic separation of the analyte using a mobile phase containing 5mM ammonium acetate in water and methanol (20:80) at a flow rate of 1 mL/min which was followed by detection with mass spectrometry.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),[ml] / [min],1,251659,DB00412,Rosiglitazone
,21502071,m/,The mass transition ion-pair was followed as m/z 358.0 for rosiglitazone and m/z 308.8 for alprazolam.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),,358.0,251660,DB00412,Rosiglitazone
,21502071,m/z,The mass transition ion-pair was followed as m/z 358.0 for rosiglitazone and m/z 308.8 for alprazolam.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),,308.8,251661,DB00412,Rosiglitazone
,21502071,overall recovery,The overall recovery of rosiglitazone was 95.9%.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),%,95.9,251662,DB00412,Rosiglitazone
,21502071,Total elution time,Total elution time was as low as 2.5 min.,Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502071/),min,2.5,251663,DB00412,Rosiglitazone
,16027405,AUC ratio,Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/rosiglitazone in the quercetin phase (0.49 +/- 0.17) was similar to that of the placebo phase (0.47 +/- 0.14) (P = .574).,"Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027405/),,0.49,259942,DB00412,Rosiglitazone
,16027405,AUC ratio,Metabolic conversion based on the AUC ratio of N-desmethylrosiglitazone/rosiglitazone in the quercetin phase (0.49 +/- 0.17) was similar to that of the placebo phase (0.47 +/- 0.14) (P = .574).,"Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027405/),,0.47,259943,DB00412,Rosiglitazone
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264185,DB00412,Rosiglitazone
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,4.8,264186,DB00412,Rosiglitazone
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264187,DB00412,Rosiglitazone
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,1.9,264188,DB00412,Rosiglitazone
,13680854,flow-rate of the mobile phase,The flow-rate of the mobile phase was set at 1 mL/min.,Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680854/),[ml] / [min],1,269115,DB00412,Rosiglitazone
>,13680854,extraction efficiency,The extraction efficiency was >80% for both rosiglitazone and IS from human plasma.,Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680854/),%,80,269116,DB00412,Rosiglitazone
